Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Articles online first > Minerva Urologica e Nefrologica 2020 Jan 07

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Urologica e Nefrologica 2020 Jan 07

DOI: 10.23736/S0393-2249.19.03648-8

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

The utilization status of neoadjuvant chemotherapy in muscle-invasive bladder cancer: a systematic review and meta-analysis

Wei LIU 1, Jinhui TIAN 2, Su ZHANG 1, Enguang YANG 1, Haixiang SHEN 3, Fudong LI 4, Kailing LI 5, Tao ZHANG 1, Hanzhang WANG 6, Robert S. SVATEK 6, Ronald RODRIGUEZ 6, Zhiping WANG 1

1 Key Laboratory of Gansu Province for Urological Diseases, Gansu Nephro-Urological Clinical Center, Institute of Urology, Lanzhou University Second Hospital, Lanzhou, P.R. China; 2 Evidence-based Medicine Center of Lanzhou University, Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province, Lanzhou, P.R. China; 3 Department of Urology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China; 4 Department of Urology, Lanzhou General Hospital of People's Liberation Army, Lanzhou, P.R. China; 5 Department of Urology, First Hospital of Lanzhou University, Lanzhou, P.R. China; 6 Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA


PDF


INTRODUCTION: To give a comprehensive depiction of the utilization status of neoadjuvant chemotherapy (NAC) in muscle invasive bladder cancer (MIBC) worldwide.
EVIDENCE ACQUISITION: Potential relevant research papers of Pubmed, Embase, Web of Science, and the Cochrane Library were reviewed to identify eligible studies. Primary outcomes of this meta-analysis were utilization rate of NAC and its utility distribution in different genders, races, ages, countries and temporal trends. The utilization rates of NAC were calculated as ‘Proportion (s)’ with 95% confidence intervals (CIs) and pooled estimates were calculated by using a random-effect model.
EVIDENCE SYNTHESIS: A total of thirteen studies and 35,738 patients were included. The total proportion of NAC applied in MIBC populations prior to radical cystectomy (RC) was 17.2% (95% CI: 12.5%-21.9%, I2=99.7%). The comparative analyses showed there were no significant differences existing in different genders or races on NAC utilization rates. In terms of age distribution, <60 age group conferred higher utilization rate of NAC than the older (OR=1.919, 95% CI: 1.671-2.202, P=0.0001). As for regional distribution, our meta-analysis showed that Japan (Proportion: 44.0%, 95% CI: 6.5%-81.5%, I2=99.6%) and Sweden (37.9%, 95% CI: 34.9%-40.8%) were the top two leading countries which contributed to the most frequent application of NAC. In respect of pathologic responses after NAC, complete, partial and down-staged pathologic responses were achieved in 16.6% (95% CI: 7.4%-25.9%, I2=89.7%), 14.6% (95% CI: 0.8%-28.5%, I2=89.7%) and 45.0% (95% CI: 17.8%-72.2%, I2=98.8%) patients, respectively.
CONCLUSIONS: The present study shows the low utilization rate of NAC in MIBC patients. Standardization of the treatment modality of MIBC and promotion of guidelines might be necessary to expedite the adoption of NAC in near future.


KEY WORDS: Muscle invasive bladder cancer; Neoadjuvant chemotherapy; Meta-analysis

inizio pagina